SAN DIEGO, June 12, 2024 /PRNewswire/ -- Alida Biosciences (AlidaBio), an innovator in epigenomic research tools, proudly announces the successful completion of a $7.5 million Series A funding round. This funding, led by Genoa Ventures with participation from FusionX Ventures and Vertical Venture Partners, is complemented by two ongoing SBIR grants totaling $4 million from The National Human Genome Research Institute (NHGRI).

圣地亚哥，2024年6月12日/PRNewswire/--表观基因组研究工具的创新者Alida Biosciences（AlidaBio）骄傲地宣布，750万美元的a系列融资回合圆满完成。这项资金由热那亚风险投资公司牵头，FusionX风险投资公司和垂直风险投资合作伙伴参与，并得到了国家人类基因组研究所（NHGRI）正在进行的两项SBIR赠款的补充，总额为400万美元。

Additionally, AlidaBio unveils the Early Access launch of two products: the EpiPlex™ RNA Library Prep Kit and the EpiScout™ Analysis Suite. These products provide a comprehensive solution for multiplexed epitranscriptomic analysis of input-limited clinical research RNA samples, offering unprecedented sensitivity and accuracy..

此外，AlidaBio还推出了两种产品的早期Access发布：EpiPlex™RNA文库制备试剂盒和EpiScout™分析套件。这些产品为输入有限的临床研究RNA样品的多重表观转录组学分析提供了全面的解决方案，提供了前所未有的灵敏度和准确性。。

Innovative Solutions for Pioneering Research

开创性研究的创新解决方案

EpiPlex RNA Library Prep Kit is designed to revolutionize epitranscriptomic research by enabling unprecedented multiplexed detection of RNA modifications. This kit integrates a streamlined assay workflow with an intuitive bioinformatics platform, facilitating high-sensitivity analysis of RNA modifications.

EpiPlex RNA文库制备试剂盒旨在通过对RNA修饰进行前所未有的多重检测，彻底改变表转录组学研究。该试剂盒将简化的测定工作流程与直观的生物信息学平台相结合，有助于对RNA修饰进行高灵敏度分析。

The epitranscriptome, consisting of a diverse array of naturally occurring RNA modifications, plays a crucial role in regulating RNA biology, including RNA-protein interactions, splicing, three-dimensional RNA structure, transcript stability, intracellular trafficking, and translation..

表转录组由多种天然存在的RNA修饰组成，在调节RNA生物学中起着至关重要的作用，包括RNA-蛋白质相互作用，剪接，三维RNA结构，转录本稳定性，细胞内运输和翻译。。

Traditional methods, relying on antibody-based and chemical approaches, are limited to detecting a single type of modification per assay and require high input amounts of RNA. The EpiPlex kit overcomes these limitations by using non-antibody binders (NABs), which exhibit high affinity and minimal off-target binding.

依赖于基于抗体和化学方法的传统方法仅限于每次测定检测单一类型的修饰，并且需要高输入量的RNA。EpiPlex试剂盒通过使用非抗体结合物（NAb）克服了这些限制，NAb具有高亲和力和最小的脱靶结合。

This results in superior reproducibility, sensitivity, and accuracy, even with low RNA inputs. The early access launch of these products is aligned with the completion of several beta customer experiences, with customers expressing high satisfaction with the improved workflow and exceptional data quality..

即使在低RNA输入的情况下，这也会产生优异的重现性，灵敏度和准确性。这些产品的早期发布与多个测试版客户体验的完成相一致，客户对改进的工作流程和出色的数据质量表示高度满意。。

'The AlidaBio EpiPlex Library Prep Kit proved to have several advantages over alternative methods,' said beta customer Dr. Daniel Kupers of Fred Hutchinson Cancer Research Center. 'We observed ease-of-use going from input RNA to sequence-ready libraries all in one kit, time savings and usability for situations with limited amounts of RNA, and lower background than other methods.

弗雷德·哈钦森癌症研究中心（FredHutchinsonCancerResearch Center）的测试版客户丹尼尔·库珀斯（DanielKupers）博士说：“事实证明，AlidaBio EpiPlex Library Prep Kit比其他方法具有多个优势。”我们观察到从输入RNA到序列就绪文库的易用性都在一个试剂盒中，对于RNA量有限的情况，以及比其他方法更低的背景，可以节省时间和可用性。

The inclusion of bioinformatics analysis with EpiScout is also a plus, as high-quality calls are challenges with other methods.'.

将生物信息学分析纳入EpiScout也是一个优势，因为高质量的呼叫对其他方法来说是一个挑战。”。

EpiScout Analysis Suite complements the EpiPlex kit by providing an intuitive bioinformatics platform for analyzing and visualizing complex epitranscriptomic data. This suite streamlines data interpretation and offers powerful tools for researchers to explore the multifaceted landscape of RNA modifications and multiomic integration of data sets..

EpiScout分析套件通过提供直观的生物信息学平台来分析和可视化复杂的表位转录组数据，从而补充了EpiPlex试剂盒。该套件简化了数据解释，并为研究人员探索RNA修饰的多方面情况和数据集的多组学整合提供了强大的工具。。

Clinical Relevance and Applications

临床相关性和应用

The EpiPlex kit is particularly suited for profiling multiple RNA modifications in clinical research samples where RNA input is limited. Typically, tissue samples, clinical biopsies, and other native biological materials provide small quantities of total RNA, with mRNA constituting only 1-3% of this total.

EpiPlex试剂盒特别适用于分析RNA输入有限的临床研究样品中的多种RNA修饰。通常，组织样品，临床活检和其他天然生物材料提供少量总RNA，mRNA仅占总RNA的1-3%。

The EpiPlex kit's high sensitivity and efficiency make it ideal for these scenarios, ensuring high-quality results from even the smallest RNA samples. This efficiency, driven by the NABs' high affinity and specificity, ensures high-quality modification site calling without increasing sequencing depth requirements..

EpiPlex试剂盒的高灵敏度和高效率使其成为这些情况的理想选择，确保即使是最小的RNA样品也能获得高质量的结果。这种效率由NABs的高亲和力和特异性驱动，确保了高质量的修饰位点调用，而不增加测序深度要求。。

Series A Funding: A Milestone Achievement

A系列资金：里程碑式的成就

The successful Series A funding for AlidaBio underscores investor confidence in the innovative approach. This funding will facilitate faster and enhanced product development, as well as a focused effort to bring the EpiPlex kit into customers' hands, maximizing its impact in the field. 'Securing this Series A funding is a testament to the groundbreaking potential of our technology,' said Dr.

AlidaBio成功获得A系列融资，突显了投资者对创新方法的信心。这笔资金将有助于加快和改进产品开发，并集中精力将EpiPlex套件带到客户手中，最大限度地发挥其在该领域的影响力。”获得这一系列A资金证明了我们技术的开创性潜力。

Gudrun Stengel, CEO of AlidaBio. 'We are excited to introduce the EpiPlex RNA Library Prep Kit and the EpiScout Analysis Suite, and to accelerate our technology development in the multiplexed RNA modification detection space. The strong support from our investors reflects our shared enthusiasm in building research tools needed to uncover new insights into RNA biology and advance the field of epitranscriptomics.'.

AlidaBio首席执行官Gudrun Stengel说：“我们很高兴推出EpiPlex RNA文库制备试剂盒和EpiScout分析套件，并加速我们在多重RNA修饰检测领域的技术开发。投资者的大力支持反映了我们对建立研究工具的共同热情，这些工具需要揭示RNA生物学的新见解并推进表位转录组学领域。”。

The funding recognizes both the potential and immediate impact of AlidaBio's solutions. 'AlidaBio has created a technical yet elegant solution to uncover hidden regulatory information on RNA, scalable with current NGS technology,' said Landon Merrill, principal at Genoa Ventures. 'With this technology and Dr.

这笔资金认识到AlidaBio解决方案的潜在和直接影响。”热那亚风险投资公司（GenoaVentures）负责人兰登·梅里尔（LandonMerrill）说，阿里达比奥（AlidaBio）创造了一个技术性但优雅的解决方案，可以发现RNA上隐藏的监管信息，可以通过当前的NGS技术进行扩展利用这项技术和博士。

Stengel's talented team, AlidaBio is poised to lead the mainstream adoption of epitranscriptomics by the genomics customer base.'.

Stengel的天才团队AlidaBio准备领导基因组学客户群主流采用表位转录组学。”。

About AlidaBio

关于AlidaBio

AlidaBio, founded in 2020, is revolutionizing the field of epigenomics by commercializing accessible tools that broaden the application of epitranscriptomics in life sciences. Our groundbreaking products empower researchers to concurrently analyze multiple RNA modifications with relative quantification, using RNA inputs suitable for clinically relevant samples and supported by user-friendly bioinformatics..

AlidaBio成立于2020年，通过将可访问的工具商业化，拓宽了表观转录组学在生命科学中的应用，正在彻底改变表观基因组学领域。我们开创性的产品使研究人员能够同时分析多种RNA修饰，并进行相对定量，使用适合临床相关样品的RNA输入，并得到用户友好的生物信息学的支持。。

For more information about the EpiPlex RNA Reagent Kit, the EpiScout Analysis Suite, and other future products, please visit our website at www.alidabio.com or contact:

有关EpiPlex RNA试剂盒，EpiScout分析套件和其他未来产品的更多信息，请访问我们的网站www.alidabio.com或联系：

Media Contact:

媒体联系人：

Natasha Moshirian Wagner VP, Product Marketing AlidaBio Email: nwagner@alidabio.com

产品营销副总裁Natasha Moshirian Wagner AlidaBio电子邮件：nwagner@alidabio.com

AlidaBio — Redefining the frontier of RNA biology.

AlidaBio-重新定义RNA生物学的前沿。

SOURCE Alida Biosciences

源Alida生物科学